SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom (AVGO) is trending following strong Q4 earnings and an upbeat Q1 revenue forecast, driven by booming AI chip demand. The community is focused on whether AVGO's earnings call can sustain the positive momentum, especially after market concerns were raised by Oracle's recent report, with some anticipating a significant price movement post-call. Investors are weighing the company's AI prospects against valuation concerns, with comparisons to NVDA's market capitalization and revenue multiples being actively discussed.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending as investors react to earnings news and a surprise CEO departure, with community members debating whether the results justify the stock's surge. Bullish sentiment highlights a potential turnaround and strong China sales, while bears cite valuation concerns and leadership uncertainty. The stock's movement is also drawing comparisons to other retail companies and potential sector-wide recovery.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

ALT is trending amid mixed sentiment, with some community members expressing concerns about trial data and potential delays, using hashtags like #endpointfailures and #delays. Meanwhile, other investors remain bullish, emphasizing the potential of their drug and dismissing bearish arguments, while awaiting key data releases and FDA feedback. Discussions include the impact of PathAI approval and speculation around potential partnerships.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to a volatile trading day, driven by a recently announced $40M offering that sparked a sharp sell-off, overshadowing positive Q3 results. The community is debating the offering's impact, potential for a dead cat bounce, and whether it's a buying opportunity or a sign of further decline. Some traders are drawing parallels to other high-flying stocks, while others remain optimistic about MIGI's long-term prospects in the digital infrastructure space.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SOUN is trending amid analyst upgrades and community speculation about upcoming catalysts, including a presentation at the Barclays Global Technology Conference. Community members are actively debating the potential for a short squeeze, while also discussing the company's fundamentals and competition in the AI sector. Recent news of partnerships and integrations is adding to the buzz, with bulls hoping for a sustained upward move.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is trending as investors digest its latest earnings report, which revealed a revenue miss despite a beat on EPS. Community discussions are centered on the company's guidance and whether the results are strong enough to attract bulls amidst a cautious market tape.  Some analysts suggest the company's valuation is disconnected from modest growth rates, while others point to robust membership revenue and market share gains.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

RH (Restoration Hardware) is trending due to mixed reactions surrounding its earnings call and future guidance, with some questioning the CEO's commentary. The community is actively discussing the potential impact of tariffs and interest rate decisions on the luxury home furnishings sector. Bullish investors are anticipating a short squeeze, while bearish investors are pointing to a potential price drop.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as it prepares to unveil its AI and autonomy advancements, with the community eager to learn about the company's technology roadmap; discussions include expectations for hands-free driving and potential competition with Tesla. Amidst excitement for the event, some investors express concerns over capital expenditure on AI and question the timing of lidar integration, while others remain bullish, anticipating a transformative presentation.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

$YEE is trending due to strong community support and momentum, with many highlighting its potential as the next big meme coin on the Ethereum network. Bullish sentiment is fueled by comparisons to $PEPE and $DOGE, and references to a long-term prophecy, while some community members also suggest smart money is accumulating the token.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as the market eyes new all-time highs, fueled by anticipation around Broadcom's earnings and the potential impact on AI-driven stocks. Community chatter reflects a battle between bulls and bears, with debates over market manipulation and the sustainability of the current rally. Some traders are expressing concerns about overvaluation and potential corrections, while others remain optimistic, pointing to the Fed's actions and overall market momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pharvaris (NASDAQ:PHVS) Given New $30.00 Price Target at Bank of America

Bank of America increased their price objective on shares of Pharvaris from $27.00 to $30.00 and gave the company a "neutral" rating in a research note on Thursday...

Pharvaris (NASDAQ:PHVS) Given "Buy" Rating at HC Wainwright

HC Wainwright reiterated a "buy" rating and issued a $60.00 price target on shares of Pharvaris in a research report on Wednesday...

Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals

PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.

Pharvaris (NASDAQ:PHVS) Sees Large Volume Increase - Should You Buy?

Pharvaris (NASDAQ:PHVS) Sees Strong Trading Volume - Here's What Happened...

<ul class="summary-bullets"><li>Pharvaris shares jumped in early Wednesday trading after the company reported positive Phase 3 data for its oral HAE drug deucrictibant.</li><li>Results will be used to support regulatory approval filings expected in early 2026.</li><li>The drug is positioned as an oral alternative to current injectable HAE therapies, which many patients find difficult to use.</li></ul>Shares of Pharvaris (PHVS) rose in early morning trade on Wednesday after the company reported positive Phase 3 results for its oral drug deucrictibant, aimed at treating hereditary angioedema (HAE).HAE is a rare condition that causes sudden, severe swelling attacks. The RAPIDe-3 Phase 3 study is Pharvaris’ first trial for on-demand treatment of HAE attacks. The data will support marketing approval filings in early 2026.<a href="https://stocktwits.com/symbol/PHVS/sentiment">PHVS’ stock</a> rose as much as 20% in pre-market trade and was among the top trending tickers on Stocktwits. Retail sentiment around the company on the platform trended in ‘extremely bullish’ territory, accompanied by chatter at ‘extremely high’ volumes.<h2 class="st-heading-2">RAPIDe-3 Study Results</h2>The global RAPIDe-3 trial tested deucrictibant against a placebo in 134 patients across 24 countries, including adolescents and adults with different forms of HAE. The drug, taken as a 20 mg capsule, was designed for on-demand use during attacks.The results showed that the drug worked quickly and effectively. The company said patients reported initial symptom relief in just about 1.3 hours, compared with more than 12 hours for placebo. Full symptom resolution occurred in under 12 hours, compared with over a day in the placebo group. Most attacks were managed with a single capsule, and 93% of patients didn’t need extra medication.Currently, most effective HAE treatments are injections, which many patients find inconvenient. Pharvaris is working on pills that block a pathway called the bradykinin B2 receptor — the same pathway targeted by injectable drugs — to offer an easier alternative.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-climbs-above-93-000-wiping-out-over-400-million-in-shorts-bets/cLIXFLUREKy">Bitcoin Climbs Above $93,000, Wiping Out Over $400 Million In Short Bets</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stocks, shares background - stock photo (representative image courtesy of Sean Gladwell via Getty Images)

PHVS Stock Jumps After Phase 3 Trial Shows Rapid Symptom Relief For Oral HAE Treatment 

The RAPIDe-3 Phase 3 study is Pharvaris’ first trial for on-demand treatment of HAE attacks.

Equity

Pharvaris (NASDAQ:PHVS) Sets New 1-Year High - What's Next?

Pharvaris (NASDAQ:PHVS) Sets New 52-Week High - Here's Why...

Pharvaris (NASDAQ:PHVS) Sees Large Volume Increase - Still a Buy?

Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - What's Next...

Pharvaris (NASDAQ:PHVS) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen upgraded Pharvaris from a "sell" rating to a "hold" rating in a research report on Saturday...

Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume on Analyst Upgrade

Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume After Analyst Upgrade...

What is Wedbush's Estimate for Pharvaris FY2025 Earnings?

Pharvaris N.V. (NASDAQ:PHVS - Free Report) - Equities research analysts at Wedbush boosted their FY2025 earnings estimates for shares of Pharvaris in a research note issued on Wednesday, November...

Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.

Pharvaris NV

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

Current Price	$23.98
Prev Close	$23.68
Open	$23.69
Dividend Yield	0.00%
50-Day Moving Average	$23.73
Beta	0.60
Avg. Volume	328,583.74
PE Ratio	-7.36

52-Week High	$29.80
52-Week Low	$11.51
Market Capitalization	$1.52B
EPS (Annual)	-$2.69
Price to Book	4.19
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

PHVS
Pharvaris NV

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PHVS News

PHVSPharvaris NV